Plasticell and Pierre Fabre Laboratories Sign a Partnership Wednesday, February 24, 2016 Company has announced collaboration to identify natural stimulants of brown fat for treatment and prevention of obesity and diabetes.HIV Modification May Put a Twist on Vaccine and Drug Design Wednesday, February 24, 2016 Crucial HIV RNA modification called m6A influences viral replication, but wasn’t previously taken into consideration when developing anti-HIV therapies.Rapid, Highly Sensitive Diagnostics Tuesday, February 23, 2016 A portable and low-cost diagnostic device has been developed at EPFL. This microfluidic tool, which has been tested with Ebola, requires no bulky equipment. It is thus ideally suited for use in remote regions.Secret to Promising New Cancer Drug Discovered Tuesday, February 23, 2016 Researchers have resolved a mystery about how a promising new class of anti-cancer drugs, called nutlins, work - paving the way for improving the future of cancer treatment.BioAgilytix Acquires IPM Biotech Tuesday, February 23, 2016 BioAgilytix has announced the acquisition of IPM Biotech, a German-based bioanalytical contract research laboratory renowned for its expertise in large molecule bioanalysis, particularly in the area of immunogenicity. Myriad Expands Collaboration with TESARO, Merck Tuesday, February 23, 2016 Companion diagnostic portfolio to evaluate treatment response in patients with triple negative breast cancer or ovarian cancer.Axol Appoints Paul Andrews to Scientific Advisory Board Tuesday, February 23, 2016 Phenotypic drug discovery expert joins the stem cell disease model specialists.Cell Marker for Leukemia-Initiating Capacity Friday, February 19, 2016 University of Alabama at Birmingham researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia, or CML, today — an inability to get patients off treatment.Thermo, Children’s Hospital Los Angeles Partner Friday, February 19, 2016 Children’s Hospital Los Angeles (CHLA) and Thermo Fisher Scientific have agreed to develop a next-generation sequencing (NGS)-based panel designed specifically for pediatric cancer research. The assay would be CHLA’s first NGS panel designed to target biomarkers associated with childhood cancers.